GSK disagrees with California court ruling on Zantac litigation, shares down 4%

By - Reuters

(Adds shares down)

March 24 (Reuters) - GSK Plc said on Friday it "respectfully disagrees" with a ruling by a California state court in litigation related to claims that the company's heartburn drug, Zantac, caused cancer.

The London-listed shares of the company were down about 4% as of 1020 GMT. (Reporting by Aby Jose Koilparambil in Bengaluru; Additional reporting by Maggie Fick in London; editing by Shinjini Ganguli)